王国保

Baseline anti-PLA2R antibody titer predicts treatment response and renal outcomes in rituximab-treated membranous nephropathy

Abstract Introduction As rituximab (RTX) has become a first-line therapy for idiopathic membranous nephropathy (IMN), identifying baseline predictors of treatment response is crucial for personalized management. This study was conducted to evaluate whether baseline anti-PLA2R tit...